RecruitingNot ApplicableNCT07037563

Developing an AI Pharmacy Chatbot for the Population of Hong Kong


Sponsor

The University of Hong Kong

Enrollment

280 participants

Start Date

Jun 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The primary objective of this study is to is to develop a conversational AI service (chatbot) in Hong Kong to assist patients and caregivers with inquires related to Hospital Authority (HA)-prescribed medications, and to evaluate its effectiveness in answering medication-related questions. The main questions it aims to answer are: 1. How satisfied are the patients and caregivers with this pharmacy chatbot? 2. How will the pharmacy chatbot impact eligible patients or caregivers on their (or the patient they are caring for) medication adherence, knowledge, and the consultation time with HA pharmacists? There will be an intervention group and a control group: 1. The intervention group will be invited to use the AI Pharmacy Chatbot online for 7 days through WhatsApp, a commonly used social media platform in Hong Kong. They can inquire about their medications prescribed under HA and get instant, validated answers from the chatbot. 2. The control group will not use the chatbot during the intervention period. To evaluate the chatbot's usability, researchers will measure patient satisfaction through usability questionnaires issued to the intervention group after their intervention period. Differences in medication adherence, medication knowledge, and HA pharmacist consultation time will also be measured between the intervention and control groups after the intervention period, to determine the chatbot's impact.


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Patients aged 18 years or older diagnosed with either hyperglycaemia, hypertension, or hyperlipidaemia, and currently receiving medication prescribed by the Hospital Authority in Hong Kong.
  • Caregivers aged 18 years or older for patients described above.

Interventions

OTHERAn AI pharmacy chatbot offering information related to HA-prescribed medication for hyperglycaemia, hypertension, and hyperlipidaemia

It is a chatbot for HA-prescribed medication used for treating hyperglycaemia, hypertension, and hyperlipidaemia, available through WhatsApp. All the responses will be extracted from a database, in which the content was obtained from and validated by pharmacists from the Chief Pharmacist's Office of the Hospital Authority in Hong Kong. The intervention period will last for 7 days.


Locations(2)

Laboratory of Data Discovery for Health

Hong Kong, Hong Kong

The University of Hong Kong

Hong Kong, Hong Kong

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07037563


Related Trials